Tryp Therapeutics Inc (TRYP) Corporate Media Kit

In addition, Tryp Therapeutics is diversifying its pipeline and broadening its market potential by targeting Binge Eating Disorder, which affects up to 3.5% of female patients and 2% of males, as well as Hypothalamic Obesity, which has no current FDA-approved therapies. (https://www. nationaleatingdisorders.org/statistics-research-eating-disorders ).